Oncology Corporate Profile
Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the development of drugs for orphan diseases in oncology, with Topotarget, a Danish biopharmaceuticals company based in Copenhagen, also a specialist in the development of oncology products.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Livatag® / BA-003||nanoparticle doxorubicin||Hepatocellular carcinoma (HCC)||III|
|Clonidine Lauriad® / BA-028||alpha 2 adrenoreceptor agonist||Oral mucositis with Head & Neck cancer||II|
|AMEP® / BA-015||anti-angiogenic and anti-proliferative peptide||1st line metastatic Melanoma||I|
|Fentanyl Lauriad® / BA-041||Mu opioid receptor agonist||Cancer pain||I|
View additional information on product candidates here »
8/29/2016 06:05 am
[at noodls] - Tokyo, Japan - 29 August 2016: Sosei Group Corporation (TSE Mothers Index: 4565) hereby announces that its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole ...